Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 05, 2025 08:30 ET | Source: Autonomix Medical, Inc.

Autonomix Highlights Compelling Patient Testimonial Showing Rapid Pain Relief from First-in-Human Proof-of-Concept Trial in Pancreatic Cancer Pain

Video testimonial demonstrates pain reduction after transvascular nerve ablation, suggesting potential for improving quality of life in late-stage cancer care Patient testimonial now available here ...
April 30, 2025 08:15 ET | Source: Autonomix Medical, Inc.

Autonomix Medical, Inc. Reports Positive Outcomes in Initial Phase of First-in-Human Proof-of-Concept Trial in Pancreatic Cancer Pain and Initiates Market Expansion Study for Visceral Cancer Pain

Initial trial phase (“PoC 1”) achieved key learnings and met all study objectives Clinically meaningful pain reduction with 100% of responders achieving zero opioid use at 7 days post-procedure and...
September 07, 2023 13:30 ET | Source: Berkshire Sterile Manufacturing

Berkshire Sterile Manufacturing to Host Webinar on Formulation Development for First-in-Human Studies

Lee, MA, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Berkshire Sterile Manufacturing (BSM) is pleased to announce their ninth webinar in their webinar series, Sterile Filling 101, which will be held on...
January 24, 2023 08:00 ET | Source: Pharmaceutics International Inc.

Pii Congratulates Skye Bioscience for First-in-Human Phase 1 Trial of Proprietary Cannabinoid Derivative and Nanoemulsion Formulation Designed to Potentially Treat Glaucoma.

Hunt Valley, MD, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Pharmaceutics International, Inc. (Pii), a contract development and manufacturing organization (CDMO), proudly celebrates a first-in-human Phase I...
May 21, 2019 09:30 ET | Source: PAVmed Inc.

PAVmed Reports First Quarter 2019 Financial Results and Provides Business Update

Conference call to be held on May 21, 2019 at 4:30 p.m. Eastern time NEW YORK, May 21, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly...
May 20, 2019 09:30 ET | Source: PAVmed Inc.

PAVmed Announces First Human CarpX™ Procedures

First nine patients undergo successful CarpX procedures as part of FIH clinical safety study NEW YORK, May 20, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or...
December 06, 2013 06:10 ET | Source: Rhizen Pharmaceuticals SA

Rhizen Pharmaceuticals S.A. announces initiation of a "First in Human" Phase-1 trial of RP6530, a dual PI3K delta/gamma inhibitor, in patients with hematological malignancies

La Chaux-de-Fonds, Switzerland, Dec. 6, 2013 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. today announced the initiation of a "first in human" Phase-1 study of RP6530, a...